Bayer’s rally now hinges on one Missouri hearing
Published on 07/18/2026 at 04:42 | Redaktion boerse-global.de
Bayer’s latest share-price move has less to do with day-to-day trading and more to do with a court calendar. The stock closed the week at EUR 48.17, up 1.35% on the day but still down 4.12% over the week, as investors reassessed what the next legal milestone could mean for the company’s long-running Roundup dispute.
The immediate catalyst is a delay. A Missouri court has pushed back the hearing on the proposed USD 7.25 billion settlement to 19 August from an originally planned date in early July. That hearing is the so-called fairness hearing, a step that is necessary before any final approval can be granted. Even then, the deal would still remain vulnerable to appeals.
That matters because the Supreme Court win on 25 June 2026, in Monsanto v Durnell, was only part of the story. By a 7:2 vote, the US Supreme Court ruled in Bayer’s favour, strengthening the company’s preemption argument and making it harder to pursue certain federal claims tied to allegations that Roundup failed to warn about cancer risks. Bayer says this removes a major legal burden, and the decision could weaken many of the roughly 65,000 remaining cases.
Yet the settlement itself is not finished. Bayer said in its quarterly report that the mass settlement will only take effect once all appeal proceedings are complete, a process that could take several years. The hearing in Missouri is therefore not a final victory lap, but an important checkpoint in a much longer sequence.
Should investors sell immediately? Or is it worth buying Bayer?
For investors, the appeal of the bullish case is straightforward. The Supreme Court decision may reverberate far beyond one case, and the settlement process has already advanced far enough that the opt-out deadline for claimants has passed. That limits the number of ways the deal can still be derailed. The stock’s performance reflects that improved backdrop: it is 72.68% above its level from 12 months ago and up 30.15% since the start of the year. Its RSI stands at 59.5, which does not point to an overbought market.
The operating picture offers some support too. Bayer reported quarterly revenue of EUR 13.405 billion, up 4.1% on a currency- and portfolio-adjusted basis, while EBITDA before special items rose 9.0% to EUR 4.453 billion. Crop Science posted higher sales and a marked improvement in earnings, and management expects a partial recovery in glyphosate volumes, especially in Latin America in the second half.
Still, the legal overhang has not disappeared, and neither has the financial strain. Fitch has kept a negative outlook despite the Supreme Court ruling, citing ongoing operational uncertainty. On top of that, Bayer’s net financial debt rose to EUR 32.518 billion as of 31 March 2026, after being lower at the end of 2025. The company also expects around EUR 5 billion in legal payments in 2026, and says net debt could reach EUR 32 billion to EUR 33 billion by year-end.
The first quarter showed how quickly those cash demands can bite. Free cash flow came in at minus EUR 2.320 billion, while payments to resolve PCB and glyphosate litigation produced a net cash outflow of EUR 2.002 billion. Meanwhile, glyphosate sales were weak: herbicide revenue fell 10.2%, and glyphosate-containing products dropped 15.1%, with customers in North America and Europe, the Middle East and Africa delaying purchases.
Bayer has also opened a new front by asking US trade authorities in late June, via Monsanto, to impose anti-dumping and countervailing duties on glyphosate imports from China. That move has not produced a result yet, but it shows the company is trying to address pricing pressure from another angle.
Bayer at a turning point? This analysis reveals what investors need to know now.
The chart still leaves room for more upside if the legal process continues to move in Bayer’s favour. The stock is trading at EUR 48.29 in one recent reading and sits a little over 10% below its 52-week high of EUR 53.86. Annualised volatility is 62.04%, a reminder that court headlines can still move the share price sharply in either direction.
For now, the next date to watch is clear: 19 August 2026 in Missouri. If the court signs off on the USD 7.25 billion deal without new complications, the market is likely to keep rewarding Bayer’s reduced legal risk. If the hearing slips again, or if appeals and objections muddy the process, the rally will have to fight for direction.
Ad
Bayer Stock: New Analysis - 18 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
